Literature DB >> 6813496

Distribution of gold in serum erythrocytes and white blood cells after in vitro incubation and during chrysotherapy with different gold compounds.

J D Herrlinger, C Alsen, R Beress, U Hecker, W Weikert.   

Abstract

We examined the binding of gold to serum proteins and the gold level in serum and in blood cells both after incubation in vitro and under longterm treatment with 3 gold compounds. Gold was measured by atomic absorption spectrophotometry, a serum fractionated by gel chromatography; blood cells were separated by gradient centrifugation, and intracellular gold was measured after pressure decomposition and MIBK-extraction. Aurothiomalate (GSTM), gold keratinate (GK), and auranofin (AF) were used. AF showed the highest binding to globulins in in vitro and in vivo. With GSTM and GK there were no measurable amounts of gold in the red cell lysate or erythrocyte membranes whereas with AF 40% of gold was localized within erythrocytes. The amount of gold in granulocytes and mononuclear cells after incubation with AF is considerably higher than with GK and GSTM.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6813496

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  6 in total

Review 1.  Clinical pharmacokinetics of oral and injectable gold compounds.

Authors:  K L Blocka; H E Paulus; D E Furst
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

2.  Serum gold concentrations during treatment with auranofin.

Authors:  P L Van Riel; F W Gribnau; L B Van de Putte; C W Arts; A Van Aernsbergen
Journal:  Clin Rheumatol       Date:  1987-03       Impact factor: 2.980

Review 3.  Current status of disease-modifying drugs in progressive rheumatoid arthritis.

Authors:  J D O'Duffy; H S Luthra
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

4.  Antiarthritic synergism of combined oral and parenteral chrysotherapy. II. Increased inhibition of activated leukocyte oxygen burst by combined gold action.

Authors:  A E Finkelstein; M Ladizesky; R Borinsky; E Kohn; I Ginsburg
Journal:  Inflammation       Date:  1988-08       Impact factor: 4.092

Review 5.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

6.  Comparative pharmacokinetics of triethylphosphine gold (auranofin) and gold sodium thiomalate (GST).

Authors:  D E Furst; S H Dromgoole
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.